RPT-BUZZ-PREVIEW: Johnson & Johnson down ahead of quarterly earnings report

Repeats Tuesday's BUZZ with no changes to text

** Shares of Johnson & Johnson JNJ.N down 0.1% to $218.39 ahead of quarterly earnings due before the opening bell on Wednesday

** Wall Street analysts expect JNJ to report ~7.3% growth in rev to ~$24.16 bln as well as a ~20% jump in adj EPS to $2.44

** JNJ's rev and adj EPS have met or exceeded analyst expectations every time over the last 8 quarters

** JNJ won exemption from U.S. tariffs after reaching an agreement with the Trump administration to lower drug prices

** In November, JNJ said it would buy Halda Therapeutics for $3.05 billion in cash, expanding its presence in solid tumors and prostate cancer treatments

** Among 28 analysts covering JNJ, avg rating is "BUY" and median PT is $211.04

** JNJ options imply a 3.3% swing for the shares, in either direction, by Friday; that's higher than the stock's avg move, on the day of results, of 2.2%, over the last eight qtrs, according to Trade Alert

** JNJ is up 5.6% YTD vs 0.2% rise in S&P 500 healthcare index .SPXHC

(Reporting by Chibuike Oguh in New York; additional reporting by Saqib Ahmed)

((Email: Chibuike.Oguh@thomsonreuters.com; Phone: +332-219-1834; Reuters Messaging: chibuike.oguh.thomsonreuters.com@reuters.net))